The Serum Institute of India has already established production capacity for 100 million doses per annum, which will be doubled over the next two years, the sta... The Serum Institute of India has already established production capacity for 100 million doses per annum, which will be doubled over the next two years, the statement said.
The R21/Matrix-M malaria vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax's adjuvant technology, has been recommended for use by the World Health Organization (WHO) after meeting required safety, quality and effectiveness standards.
Adar Poonawalla, CEO, of Serum Institute of India, in an official statement, said, "For far too long, malaria has threatened the lives of billions of people across the globe, disproportionately affecting the most vulnerable amongst us. This is why the WHO recommendation and approval of the R21/Matrix-M vaccine marks a huge milestone on our journey to combat this life-threatening disease, showing what exactly can be achieved when the public and private sector, scientists and researchers, all work together towards a shared goal."
Strategic Alliance Management Services Pvt Ltd.
1/1-B (Ground Floor) Choudhary Hetram House
Bharat Nagar, New Friends Colony
New Delhi-110 025 011 4081 9900
Our regular working hours are from 09:00 AM to 07:00 PM. Please note that our office remains closed on the second and fourth Saturdays of every month, as well as on national public holidays. Additionally, if a fifth Saturday falls within a month, we will also be closed on that day.